OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
Zhiwei Zheng, Ling Fang, Hongfu Cai, et al.
Immunotherapy (2023) Vol. 15, Iss. 13, pp. 1045-1055
Closed Access | Times Cited: 4
Zhiwei Zheng, Ling Fang, Hongfu Cai, et al.
Immunotherapy (2023) Vol. 15, Iss. 13, pp. 1045-1055
Closed Access | Times Cited: 4
Showing 4 citing articles:
A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial
Jiahui Li, Chaoqun Xu, Suyun Yuan
Cost Effectiveness and Resource Allocation (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Jiahui Li, Chaoqun Xu, Suyun Yuan
Cost Effectiveness and Resource Allocation (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China
Chaoneng He, Xiufang Mi, Gaoqi Xu, et al.
PLoS ONE (2024) Vol. 19, Iss. 5, pp. e0302961-e0302961
Open Access
Chaoneng He, Xiufang Mi, Gaoqi Xu, et al.
PLoS ONE (2024) Vol. 19, Iss. 5, pp. e0302961-e0302961
Open Access
Sugemalimab combined with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis
Hongfu Cai, Ling Fang, Zhiwei Zheng
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Hongfu Cai, Ling Fang, Zhiwei Zheng
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial
Heng Xiang, Kehui Meng, Mei-Yu Wu, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2024) Vol. 24, Iss. 8, pp. 1043-1051
Closed Access
Heng Xiang, Kehui Meng, Mei-Yu Wu, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2024) Vol. 24, Iss. 8, pp. 1043-1051
Closed Access
